Navigation Links
Sharp rise in cases of new strain of whooping cough

Australia's prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

A team of Australian scientists, led by the University of New South Wales (UNSW), believe this emerging new genotype (called prn2-ptxP3) of the Bordetella pertussis bacterium may be evading the protective effects of the current acellular vaccine (ACV), and increasing the incidence of the potentially fatal respiratory illness, according to the study published in The Journal of Infectious Diseases.

The new genotype also has been detected in other countries, suggesting it has the potential to spark epidemics elsewhere and should be closely monitored, the researchers warn.

"The prolonged whooping cough epidemic in Australia that began during 2008 has been predominantly caused by the new genotype of B. pertussis," said one of the study authors, Associate Professor Ruiting Lan, of the UNSW School of Biotechnology and Biomolecular Sciences.

"The genotype was responsible for 31 percent of cases in the 10 years before the epidemic, and that's now jumped to 84 percent a nearly three-fold increase, indicating it has gained a selective advantage under the current vaccination regime.

"The vaccine is still the best way to reduce transmission of the disease and reduce cases, but it appears to be less effective against the new strain and immunity wanes more rapidly. We need to look at changes to the vaccine itself or increase the number of boosters," Associate Professor Lan said.

Last year about 38,000 cases of the life-threatening disease were reported nationally, despite Australians having a relatively high vaccine uptake.

The authors said the increase in the number of whooping cough notifications may be partly due to recent improvements in diagnostic tests, which means that mild or atypical cases in older children or adults are now more likely to be correctly identified. However, this does not explain the marked increase in hospital admissions, especially of very young children who are not fully immunised, in whom the diagnosis is much easier.

Associate Professor Lan's laboratory team led by postdoctoral research associate Dr Sophie Octavia analysed close to 200 samples of the B. pertussis bacterium, collected from 2008 to 2010 over four states, NSW, Vic, SA and WA.

The team worked closely with researchers from the Centre for Infectious Diseases and Microbiology at Westmead (A/Prof Vitali Sintchenko and Prof Lyn Gilbert), Women's and Children's Hospital, Adelaide (Dr Andrew Lawrence), Princess Margaret Hospital for Children, Perth (Dr Tony Keil); and Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne (Dr Geoff Hogg).

The findings suggest that while the current vaccination remains effective against most forms of whooping cough, its use could be contributing to the emergence of new and potentially more dangerous clones, Associate Professor Lan said.

First introduced in Australia in 1997, the ACV vaccination replaced the whole-cell vaccine (WCV), due to concerns about the latter's side-effects.

"The whole cell vaccine contained hundreds of antigens, which gave broad protection against many strains of B. pertussis," said Associate Professor Lan. "But the acellular vaccine contains only three to five antigens.

"If the ACV is less effective against these new strains, we need to ask what other strategies can be used to combat the epidemic, which is ongoing."

There has been growing concern among public health officials about the rising incidence of whooping cough in Australia. The death rate for babies under the age of six months who catch pertussis is one in 200, according to NSW Health, which says adults and adolescents are at particular risk of contracting the disease and can pass it on to babies who are too young to be immunised.

In NSW, vaccinations are routinely given to infants at two, four and six months. The first dose can be given as early as 6 weeks of age. Boosters are needed at age four and again in high school. NSW Health also recommends that new parents and carers of young infants receive boosters.


Contact: Ruiting Lan
University of New South Wales

Related medicine news :

1. Short, sharp shock treatment for E. coli
2. Sharp decrease in deaths from sudden cardiac arrest
3. Poorer Americans See Sharper Health Declines With Age
4. Staying Sharp in New Haven: Yale brain experts discuss successful aging at free forum
5. More Evidence That Exercise May Keep The Brain Sharp
6. New method for measuring Parkinsons disease prevalence reveals sharp increase in Israel
7. Massachusetts Study Shows Sharp Rise in Early Autism Diagnoses
8. Socializing May Keep Elderly Minds Sharp
9. Sharpened focus: Improving the numbers, utility of medical imaging
10. HIV rate in SF could be cut sharply with expanded treatment, study predicts
11. Brain injuries rise sharply in minor hockey after bodychecking rules relaxed: Study
Post Your Comments:
(Date:12/1/2015)... Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... United States, today announced that its iconic bottle has won top honors in Beverage ... category. The Company also announced that it has been selected as a 2015 ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic ... United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a ... catastrophic contributors to diseases of the diabetic foot. The American Board of ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... India and PITTSBURGH , ... today announced that it expects to be the first ... markets funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate ... mg) for $99 per patient, per year. Mylan partnered ... TLE400. The significantly reduced price could generate savings of ...
(Date:12/1/2015)... Breg, Inc ., a premier provider ... it has been awarded three contracts by Novation, a ... will have access to improved pricing for Breg,s portfolio ... goods dedicated to advancing orthopedic care.  ... population, rising prevalence of chronic conditions and the health ...
Breaking Medicine Technology: